SRZN vs SVRA

Surrozen, Inc. vs Savara, Inc. — Valuation Comparison 2026

SRZN

Biotechnology
Surrozen, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$26.16
Last close
Models
8/13
Active
VS

SVRA

Biotechnology
Savara, Inc.
Quality
4.5
out of 10
Value Trap
30
LOW
Price
$5.09
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType SRZN Fair ValueSRZN Upside SVRA Fair ValueSVRA Upside
Bayesian DCF Intrinsic $11.85 -54.7% $1.41 -72.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.60 -89.0% $0.40 -92.2%
Dynamic NAV Asset-Based $0.88 -97.3% $0.93 -81.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SRZN vs SVRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SRZN vs SVRA — Which Stock Is More Undervalued?

SVRA scores higher with a 4.5/10 quality rating vs SRZN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Surrozen, Inc. (SRZN) and Savara, Inc. (SVRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SRZN currently trades at $26.16 with a QOC of 4.1/10, while SVRA trades at $5.09 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).